The United Laboratories International Holdings (3933) Fundamentals 2026 — P/E 7.0x, Revenue Analysis | SniperIQ
The United Laboratories International Holdings (3933) is a HK-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of HK
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is The United Laboratories International Holdings's market cap?
The United Laboratories International Holdings (3933) has a market capitalization of approximately HK
What is The United Laboratories International Holdings's P/E ratio?
The United Laboratories International Holdings's trailing twelve-month P/E ratio is 7.0x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is The United Laboratories International Holdings?
The United Laboratories International Holdings runs a net profit margin of 15.8%, a gross margin of 41.7%, and an operating margin of 17.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does The United Laboratories International Holdings generate?
The United Laboratories International Holdings reported revenue of ¥13.2B for fiscal year 2025, with net income of ¥2.1B and earnings per share (EPS) of 1.11. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does The United Laboratories International Holdings pay a dividend?
The United Laboratories International Holdings offers a trailing dividend yield of about 3.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is The United Laboratories International Holdings financially healthy?
The United Laboratories International Holdings carries a debt-to-equity ratio of 0.29x and a current ratio of 1.83x, with a market beta of 0.29. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is The United Laboratories International Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For The United Laboratories International Holdings (3933) the key facts are: market cap HK
Track The United Laboratories International Holdings's full fundamentals live
Get The United Laboratories International Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.